Phase II Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Trial Profile

Phase II Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Ponatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Filgrastim; Mesna; Methotrexate; Methotrexate; Rituximab; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.
    • 07 Sep 2017 Planned primary completion date changed from 1 Aug 2023 to 1 Dec 2023.
    • 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top